Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion

Inmune Bio ( (INMB) ) has provided an update.

INmune Bio Inc. has prepared a presentation slide deck to be used in future presentations, highlighting their progress in developing immunotherapies. The company is advancing its late-stage pipeline with key programs like CORDStrom and XPro, targeting rare pediatric diseases and Alzheimer’s, respectively. They have completed Phase 2 trials for both programs and are planning regulatory filings and Phase 3 trials in the coming years. This strategic progression positions INmune Bio for regulatory acceleration and potential market entry, which could significantly impact their market presence and stakeholder interests.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies targeting innate immune dysfunction in rare pediatric inflammatory diseases and inflammatory neurologic diseases. The company is listed on NASDAQ under the ticker INMB and is involved in developing therapies such as CORDStrom for ultra-rare pediatric diseases and XPro for early Alzheimer’s disease.

Average Trading Volume: 560,259

Technical Sentiment Signal: Sell

Current Market Cap: $43.33M

See more data about INMB stock on TipRanks’ Stock Analysis page.